7.03

3.53% 0.24

After Hours: 6.99 -0.04 -0.57%

Altimmune Inc (ALT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Altimmune Inc stock is traded at $7.03, with a volume of 1.67M. It is up +3.53% in the last 24 hours and up +12.84% over the past month. Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Previous Close:

$6.79

Open:

$6.76

24h Volume:

1.67M

Relative Volume:

0.78

Market Cap:

$499.63M

Revenue:

$409.00K

Net Income/Loss:

$-101.35M

P/E Ratio:

-4.3129

EPS:

-1.63

Net Cash Flow:

$-71.49M

1W Performance:

-4.48%

1M Performance:

+12.84%

6M Performance:

-3.70%

1Y Performance:

+156.57%

1-Day Range:

$6.64

$7.03

1-Week Range:

$6.45

$7.31

52-Week Range:

$2.315

$14.84

Altimmune Inc Stock (ALT) Company Profile

Name

Altimmune Inc

Sector

Healthcare (1181)

Industry

Biotechnology (671)

Phone

(240) 654-1450

Address

910 CLOPPER ROAD, GAITHERSBURG, MD

Employee

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

ALT's Discussions on Twitter

Altimmune Inc Stock (ALT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-29-24	Downgrade	Guggenheim	Buy → Neutral
Jan-24-24	Initiated	Goldman	Neutral
Mar-22-23	Downgrade	Goldman	Buy → Neutral
Dec-01-22	Initiated	Goldman	Buy
Dec-29-21	Resumed	Jefferies	Buy
Jun-02-21	Initiated	H.C. Wainwright	Buy
Feb-11-21	Initiated	Guggenheim	Buy
Dec-14-20	Initiated	Jefferies	Buy
Nov-12-20	Reiterated	B. Riley Securities	Buy
Sep-25-20	Initiated	B. Riley FBR	Buy
Aug-14-20	Initiated	Evercore ISI	Outperform
Jul-31-20	Initiated	Piper Sandler	Overweight
Jul-28-20	Initiated	JMP Securities	Mkt Outperform
Feb-24-20	Resumed	ROTH Capital	Buy
Jul-19-19	Initiated	ROTH Capital	Buy
Oct-09-17	Initiated	Piper Jaffray	Overweight

View All

Altimmune Inc Stock (ALT) Latest News

04:17 AM

Altimmune (ALT) to Release Quarterly Earnings on Tuesday - MarketBeat

04:17 AM

Nov 04, 2024

Altimmune’s stock soars more than 40% after biopharma company says trial of obesity drug led to weight loss - MSN

Nov 04, 2024

Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 - StockTitan

Nov 04, 2024

Oct 30, 2024

Thinking about buying stock in Minim, Aurora Innovation, Altimmu - GuruFocus.com

Oct 30, 2024

Regulatory And Clinical Catalysts Ahead For Altimmune (NASDAQ:ALT) - Seeking Alpha

Oct 28, 2024

Oct 26, 2024

When (ALT) Moves Investors should Listen - Stock Traders Daily

Oct 26, 2024

Oct 25, 2024

Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: C - GuruFocus.com

Oct 25, 2024

Altimmune Jumps 66% After Positive Results for Its Obesity Drug - MSN

Oct 25, 2024

Oct 24, 2024

Altimmune, Inc. (NASDAQ:ALT) Receives $18.80 Average Target Price from Brokerages - MarketBeat

Oct 24, 2024

Oct 23, 2024

SG Americas Securities LLC Sells 220,135 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat

Oct 23, 2024

Oct 17, 2024

State Street Corp's Strategic Reduction in Altimmune Inc Holdings - Yahoo Finance

Oct 17, 2024